An anti-ROR1 monoclonal antibody is currently being investigated in a phase 1 clinical trial (NCT02222688/NCT02860676) as a new treatment for CLL (Choi et al., 2015; Yu et al., 2017). The gene discussed is ROR1; the disease is B-cell chronic lymphocytic leukemia.